Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobevibart + elebsiran in chronic hepatitis D infection
ACTRN12625000416493Phase 3Active, not recruiting
- Sponsor
- Vir Biotechnology
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of tobevibart and elebsiran in hepatitis D (HDV) (2 arms), sponsored by Vir Biotechnology. Started Mar 2025; status: active, not recruiting.
02
Drugs
tobevibartelebsiran
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on ACTRN12625000416493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000416493.